Bourcier, Jessie

Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors

Wang, E., Mi, X., Thompson, M. C., Montoya, S., Notti, R. Q., Afaghani, J., Durham, B. H., Penson, A., Witkowski, M. T., Lu, S. X., et al. (2022) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 272

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M. C., Chirino, A., Jahn, J., Sondhi, A. K., Gajewski, S., Tan, Y. S. (., et al. (2024) · Science

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 175

E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

Bewersdorf, J. P., Stahl, M., Taylor, J., Mi, X., Chandhok, N. S., Watts, J., Derkach, A., Wysocki, M., Lu, S. X., Bourcier, J., et al. (2023) · Leukemia

Acute Myeloid Leukemia ResearchRNA Research and Splicing

Cited by 62